A Phase III Study to Assess the Effect of AZD0780 on LDL-C in Patients With Clinical ASCVD or at Risk for a First ASCVD Event
NCT07000123
Recruiting
This is a study to evaluate the efficacy and safety of AZD0780 in adults with clinical ASCVD or who are at risk for a first ASCVD event and who have elevated LDL-C. AZD0780 is a small molecule that reduces the amount of LDL-C in the blood. Placebo will be used for comparison, and neither the participants nor the Investigators will know who is receiving the AZD0780 medication and who is receiving the placebo until the end of study. The total length of the study for an individual participant will... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/22/2025
Locations: Research Site, Huntsville, Alabama +492 locations
Conditions: Cardiovascular Disease
Register for Updates
Study of Denikitug (GS-1811) Given Alone or With Zimberelimab in Adults With Advanced Solid Tumors
NCT05007782
Recruiting
This is a first-in-human (FIH) study to evaluate the safety and tolerability and to determine the maximum tolerated dose (MTD) and/or the recommended Phase 2 dose (RP2D) of denikitug (also known as GS-1811) as monotherapy and in combination with zimberelimab in participants with advanced solid tumors. This study will be conducted in 6 parts (Parts A, B, and E: monotherapy, Parts C and D: combination therapy, and Part F for both monotherapy and combination therapy) in participants with advanced... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/22/2025
Locations: University of California San Diego, La Jolla, California +25 locations
Conditions: Advanced Solid Tumor
Register for Updates
A Clinical Trial to Investigate the Effect of Pollen Extracts on Menopausal Symptoms in Healthy Women.
NCT06889753
Recruiting
The goal of this study is to investigate the effect of pollen extracts on menopausal symptoms in healthy women The main question it aims to answer is: What is the difference in change in severity of menopausal symptoms as assessed by the total Menopause Rating Scale (MRS) score from baseline at Week 36 between Graminex Water Soluble Pollen Extract (WSPE), Lipid Soluble Pollen Extract (LSPE), and Placebo? Participants will be asked to complete the MRS assessment tool to rate their menopausal sy... Read More
Gender:
FEMALE
Ages:
Between 45 years and 65 years
Trial Updated:
07/22/2025
Locations: KGK Science Inc., London, Ontario
Conditions: Menopausal Women
Register for Updates
Using a Blood Test to Monitor Metastatic Breast Cancer Treatment
NCT05804578
Recruiting
The goal of this observational study is to assess the effectiveness of the mDETECT breast cancer blood test at monitoring treatment response in women with metastatic breast cancer undergoing treatment.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
07/22/2025
Locations: Kingston Health Sciences Centre - Cancer Centre of Southeastern Ontario, Kingston, Ontario +1 locations
Conditions: Metastatic Breast Cancer
Register for Updates
A Clinical Efficacy and Safety Study of OHB-607 in Preventing Bronchopulmonary Dysplasia in Extremely Premature Infants
NCT03253263
Recruiting
The purpose of this study is to determine if an investigational drug can prevent Bronchopulmonary Dysplasia, reducing the burden of chronic lung disease in extremely premature infants, as compared to extremely premature infants receiving standard neonatal care alone.
Gender:
ALL
Ages:
Between 0 hours and 24 hours
Trial Updated:
07/22/2025
Locations: Arkansas Children's Hospital, Little Rock, Arkansas +60 locations
Conditions: Retinopathy of Prematurity (ROP), Intraventricular Hemorrhage, Bronchopulmonary Dysplasia, Chronic Lung Disease of Prematurity
Register for Updates
A Phase III Study to Assess the Effect of AZD0780 on LDL-C in Patients With HeFH
NCT07000136
Recruiting
This is a study to evaluate the efficacy and safety of AZD0780 in adults with HeFH and elevated LDL-C, either with clinical ASCVD and LDL-C levels of 55 mg/dL or higher or without clinical ASCVD and LDL-C levels of 70 mg/dL or higher. AZD0780 is a small molecule that reduces the amount of LDL-C in the blood. Placebo will be used for comparison, and neither the participants nor the Investigators will know who is receiving the AZD0780 medication and who is receiving the placebo until the end of st... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/22/2025
Locations: Research Site, Chula Vista, California +183 locations
Conditions: Heterozygous Familial Hypercholesterolaemia
Register for Updates
Eflornithine (DFMO) and Etoposide for Relapsed/Refractory Neuroblastoma
NCT04301843
Recruiting
Difluoromethylornithine (DFMO) will be used in an open label, multicenter, study in combination with etoposide for subjects with relapsed/refractory neuroblastoma.
Gender:
ALL
Ages:
31 years and below
Trial Updated:
07/21/2025
Locations: University of Alabama, Children's Alabama, Birmingham, Alabama +28 locations
Conditions: Neuroblastoma
Register for Updates
Cardiovascular Consequences of Inhaled Short-acting Beta-agonist Use
NCT06027606
Recruiting
The goal of this clinical trial is to test the impact inhalers have on blood vessels in young healthy individuals. The main question it aims to answer is if long term use of asthma inhalers have any effect on the blood vessels and heart. Participants will be asked to: * Perform lung function and exercise tests * Have ultrasound images taken of the artery in their arm * Use an inhaler for 4 weeks * Visit the lab for testing on 4-6 different occasions Researchers will compare two different inhal... Read More
Gender:
ALL
Ages:
Between 18 years and 40 years
Trial Updated:
07/21/2025
Locations: Clinical Physiology Laboratory, Edmonton, Alberta
Conditions: Healthy
Register for Updates
ELIOS - Investigational Biomarkers to Track Disease Modification in Active RRMS
NCT06733922
Recruiting
The exploratory ELIOS study aims to assess the value of novel investigational Eye Movement Biomarkers (EMBs) in tracking disease-related changes among a real-world cohort of Canadian patients with active RRMS, within the context of disease-modifying treatment (i.e., ofatumumab). To that end, the study will use the patented investigational, Eye Tracking Neurological Assessment (ETNA-ProgMS) SaMD (v1.0.11 or later), which has not yet received Health Canada approval, to reliably and accurately trac... Read More
Gender:
ALL
Ages:
Between 18 years and 99 years
Trial Updated:
07/21/2025
Locations: Novartis Investigative Site, Halifax, Nova Scotia +4 locations
Conditions: Relapsing Remitting Multiple Sclerosis (RRMS)
Register for Updates
Metabolic and Behavioural Effects of CONTRAVE as Potential Mechanisms of Weight Loss in Adults With Obesity
NCT06809166
Recruiting
Obesity is a common chronic disease linked with increased risk for other illnesses and earlier death. Our team and others have shown that many bodily and psychological changes occur when individuals are on calorie-restricted diets. These changes might undermine dietary adherence and help to explain the relatively poor long-term efficacy of diets. These include increased appetite, increased food 'value' and 'wanting' that leads to overconsumption. Other factors include more sensitive sensory cues... Read More
Gender:
ALL
Ages:
Between 18 years and 64 years
Trial Updated:
07/21/2025
Locations: LEAF Weight Managment Clinic, Ottawa, Ontario +2 locations
Conditions: Obesity, Weight Loss, Weight Management, Dietary Intervention, Obesity/therapy
Register for Updates
Oral Sildenafil for Exercise Capacity, Dyspnea and Cardiopulmonary Function in COPD
NCT05061368
Recruiting
Chronic obstructive pulmonary disease (COPD) is a condition characterized by airway obstruction. Patients with COPD experience significant shortness of breath on exertion. The mechanisms responsible for shortness of breath on exertion are well understood in moderate and severe COPD, but, are poorly understood in mild COPD where symptoms appear disproportionate to the degree of airway obstruction. Mild COPD patients show an exaggerated breathing response to exercise, determined by the breathing... Read More
Gender:
ALL
Ages:
Between 40 years and 80 years
Trial Updated:
07/21/2025
Locations: Clinical Physiology Laboratory, Edmonton, Alberta
Conditions: Chronic Obstructive Pulmonary Disease
Register for Updates
Open-label Study to Assess Reduction of Background Asthma Medication While Sustaining Asthma Control and Clinical Remission With Tezepelumab in Patients 12-80yrs With Severe Asthma.
NCT06473779
Recruiting
The objective of this study is to assess the potential for tezepelumab-treated patients (subcutaneous administration) to reduce maintenance therapy without loss of asthma control in adolescent and adults with severe asthma.. Study details include: 1. The study duration will be up to 72 weeks. 2. The treatment duration will be up to 68 weeks. 3. The visit frequency will be once every 4 weeks (Q4W).
Gender:
ALL
Ages:
Between 12 years and 80 years
Trial Updated:
07/21/2025
Locations: Research Site, Palmdale, California +83 locations
Conditions: Severe Asthma
Register for Updates